Fidelity International’s Adaptimmune Therapeutics ADAP Stock Holding History

Fidelity International’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-666,891	Closed	-$7.49M	–	673
2018 Q1	$7.49M	Hold	666,891	–	–	0.02%	376
2017 Q4	$4.46M	Hold	666,891	–	–	0.01%	421
2017 Q3	$5.46M	Sell	666,891 -86,850	-12%	-$542K	0.02%	391
2017 Q2	$3.38M	Hold	753,741	–	–	0.01%	416
2017 Q1	$4.15M	Hold	753,741	–	–	0.01%	421
2016 Q4	$3.05M	Buy	753,741 +1	+0%	+$5	0.01%	435
2016 Q3	$5.31M	Hold	753,740	–	–	0.02%	386
2016 Q2	$6.14M	Hold	753,740	–	–	0.02%	368
2016 Q1	$6.13M	Hold	753,740	–	–	0.02%	364
2015 Q4	$9.09M	Buy	753,740 +666,891	+768%	+$6.53M	0.03%	336
2015 Q3	$1.04M	Hold	86,849	–	–	﹤0.01%	476
2015 Q2	$1.59M	Buy	+86,849	New	+$1.49M	0.01%	490

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity International's ADAP Position: Q2 2018 in Review

Fidelity International sold out of Adaptimmune Therapeutics (ADAP) in Q2 2018, closing a stake of 666,891 shares — an estimated $7.49M sold.

Fidelity International first reported a position in ADAP in Q2 2015 and held it in 12 quarters. The position peaked at $9.09M in Q4 2015. 86 funds tracked by Wall St. Rank hold ADAP as of Q2 2018.

Fidelity International reported no remaining Adaptimmune Therapeutics position as of Q2 2018 after selling out during the quarter.
Fidelity International sold 666,891 Adaptimmune Therapeutics shares in Q2 2018, an estimated $7.49M.
Fidelity International first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 12 quarters.
Fidelity International's Adaptimmune Therapeutics position peaked at $9.09M in Q4 2015.
86 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2018.

Based on Fidelity International's 13F filing for Q2 2018, filed 10 Aug 2018.